The Results of a Phase II Randomized Trial Comparing 5-Fluorouracil and 5-Fluorouracil Plus alpha-Interferon: Observations on the Design of Clinical Trials for Androgen-Independent Prostate Cancer

The Journal of Urology

Volumn 153, Issue 5, 1995, Pages 1587-1591

  Daliani, Danai D ^a   Eisenberg, Peter D ^a   Weems, Joan ^a   Lord, Raymond ^a   Fueger, Rebecca ^a   Logothetis, Christopher J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANDROGEN; FLUOROURACIL; PROSTATE SPECIFIC ANTIGEN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXICITY; DIAGNOSIS; HUMAN; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS;

ADENOCARCINOMA; AGED; DISEASE PROGRESSION; FLUOROURACIL; HUMANS; INTERFERON-ALPHA; MALE; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RESEARCH DESIGN; SURVIVAL RATE; TIME FACTORS;

EID: 0028988086     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)67467-6     Document Type: Article

References (32)

1. Doxorubicin, mitomycin-C, and 5-fluorouracil (DMF) in the treatment of metastatic hormonal refractory adenocarcinoma of the prostate, with a note on the staging of metastatic prostate cancer.
2. Failure of chemotherapy to prolong life in patients with metastatic prostate cancer who failed androgen deprivation.
3. Chemotherapy program of the National Prostatic Cancer Project (NPCP).
4. Comparison of 5-fluorouracil (NSC-19893) and cyclophosphamide (NSC-26271) in patients with advanced carcinoma of the prostate.
5. Fluorouracil and recombinant alpha-2a-interferon: an active regimen against colorectal carcinoma.
6. Fluorouracil and recombinant human interferon alfa-2a in the treatment of metastatic chemotherapy-refractory urothelial tumors.
7. Cytotoxic chemotherapy for hormone-refractory metastatic prostate cancer
8. Chemotherapy for hormonally refractory advanced prostate carcinoma. A comparison of combined versus sequential treatment with mitomycin C, doxorubicin and 5-fluorouracil.
9. Doxorubicin, mitomycin C and 5-fluorouracil in the treatment of hormone refractory adenocarcinoma of the prostate: a Southwest Oncology Group study.
10. Cyclophosphamide, methotrexate, and 5-fluorouracil in the treatment of metastatic prostate cancer. A Southwest Oncology Group study.
11. A phase II study of continuous infusion 5-fluorouracil in advanced hormone refractory prostate cancer. An Illinois Cancer Center study.
12. Is it justified to neglect the role of chemotherapy in the treatment of prostate cancer?
13. To what degree is chemotherapy useful in the treatment of prostatic cancer?
14. Comparison of estramustine phosphate, methotrexate and cis-platinum in patients with advanced, hormone refractory prostate cancer.
15. A comparison of hydroxyurea, methyl-chloroethyl-cyclohexynitrosurea and cyclophosphamide in patients with advanced carcinoma of the prostate.
16. A critical analysis of response criteria in patients with prostatic cancer treated with cis-diamminedichloride platinum II.
17. Chemotherapy of hormone-resistant carcinoma of the prostate: 4-Epi-rubicin weekly vs. DMF monthly
18. Randomized phase II clinical trials.
19. Measuring the quality of life of cancer patients: the Functional Living Index-Cancer: development and validation.
20. Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer.
21. Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy.
22. Phase II trial of 5-fluorouracil high-dose leucovorin calcium and dipyridamole in advanced prostate cancer
23. High-dose 24-hour infusion of 5-fluorouracil in metastatic prostate cancer. A phase II trial of the Piedmont Oncology Association.
24. A phase II study of fluorouracil and alpha interferon in hormone-refractory metastatic prostate cancer.
25. Treatment of metastatic hormone-resistant prostate cancer with sequential leucovorin and 5-fluorouracil.
26. Low-dose continuous-infusion 5-FU in hormone-refractory prostatic carcinoma.
27. Treatment of metastatic hormone-resistant prostate cancer with sequential methotrexate and 5-fluorouracil.
28. Phase I/II trial of 5-fluorouracil, allopurinol and recombinant interferon alpha-2b in patients with hormone-refractory D2 prostate cancer.
29. Hormone-refractory prostate cancer: phase I-II treatment with Cytoxan, interferon alpha-2b and infusional 5-fluorouracil.
30. Continuous infusion 5-fluorouracil and weekly doxorubicin for hormone resistant prostate cancer.
31. Long-term continuous infusion 5-fluorouracil in the treatment of metastatic prostate cancer: a phase II Mid-Atlantic Oncology Group (MAOP) Study.
32. Evaluation of 5-fluorouracil infusion and cisplatin-based combination chemotherapy in the treatment of patients with D2 hormone refractory adenocarcinoma of the prostate.